Log In
Print
BCIQ
Print
Print this Print this
 

Menveo (MenACWY-CRM vaccine)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionQuadrivalent meningitis vaccine containing antigens for type A, C, W-135 and Y bacteria
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationMeningitis
Indication DetailsVaccinate against meningococcal disease caused by Neisseria meningitides groups A, C, W-135 and Y in patients >2 months; Vaccinate against meningococcal meningitis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today